TissUse

Executive Summary

TissUse GmbH, based in Berlin, Germany, has developed a proprietary 'human-on-a-chip' platform that recreates human physiology using miniaturized multi-organ models. Founded in 2010, the company aims to revolutionize pharmaceutical development by providing more predictive safety and efficacy testing compared to traditional animal models. Their technology has the potential to significantly reduce drug development costs and timelines, while addressing ethical concerns around animal testing. The platform is protected by patents and is applicable across drug discovery, toxicology, and personalized medicine. TissUse is currently at the pre-clinical stage, focusing on validation and partnering with pharmaceutical companies. With the global push for alternative testing methods and the rising demand for more human-relevant models, TissUse is well-positioned to capture market share in the growing organ-on-a-chip sector.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Round70% success
• H1 2027Pharmaceutical Partnership for Validation Studies60% success
• H2 2026Publication of Peer-Reviewed Validation Data in a High-Impact Journal80% success